UCLA CARE Center
Offering state-of-the-art medical care and clinical trials for people living with HIV and AIDS.
About UCLA CARE Center
The UCLA Center for Clinical AIDS Research and Education (CARE) provides state-of-the-art medical care and conducts clinical trials for people living with HIV and AIDS. Our highly trained, nationally recognized physicians are leaders in the field of HIV Medicine, Infectious Diseases, Oncology and other areas relevant to the health of our patients. The CARE Center’s research team is committed to conducting a broad program of ethical and high quality clinical, behavioral and prevention research to promote the health of people living with or at risk for acquiring HIV and other infectious diseases.
A5418: Study of Tecovirimat for Human Monkeypox Virus
A5418 is a randomized, placebo-controlled, double-blind study to establish the efficacy of tecovirimat for the treatment of people with laboratory-confirmed or presumptive HMPXV disease.
MAGI: Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection
This is a Phase II, randomized, observer-blind, placebo-controlled, multi-site trial of the FDA licensed rMenB+OMV NZ vaccine, Bexsero. The targeted study population is men and women 18-50 years of age who are disproportionately vulnerable to N. gonorrhoeae infection.
New study for the treatment of latent CMV infection in HIV positive adults.
This is an open-label, controlled study, conducted at US sites to evaluate the anti-inflammatory effectiveness of the study drug letermovir in adults with HIV and asymptomatic cytomegalovirus (CMV) who are on antiretroviral therapy (ART)-mediated suppression.
Impact of host factors and COVID-19 infection on the humoral immune repertoire in treated HIV
Host factors associated with the humoral repertoire in the COVID-negative cohort enhance our understanding of these important shifts among PWH.
Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection
Symptom or viral relapse in the absence of antiviral treatment is common, but the combination of symptom and viral rebound is rare.
Development and Validation of a Liquid Chromatographic-Tandem Mass Spectrometric Assay for the Quantification of Cabotegravir and Rilpivirine from Dried Blood Spots
The authors developed and validated a novel LC-MS/MS assay for the quantification of CAB and RPV from DBS, and identified conversion factors to estimate plasma concentrations from spotted blood.
In The Know: A Community Webinar Highlighting New Insights in HIV and COVID Research
Click on the presentation title or presenter below to watch that specific presentation.
- Opening Remarks with Dr. Judith Currier
- An Update on COVID-19 Research with Dr. Eric Daar
- New Approaches in HIV Prevention with Dr. Raphael Landovitz
- An Update on COVID-19 Research with Dr. David Goodman-Mez
- An Update on HIV Cure Research with Dr. Kara Chew
- Q&A and Closing Remarks